Imagine a breakthrough that challenges the very way we think about tackling aggressive and hard-to-treat cancers—especially when traditional hormone-targeted therapies fall short. And this is the part most people miss: a new study reveals that interfering with a tiny molecule involved in energy production within cancer cells could slow down tumor growth in some of the most stubborn types of breast cancer. But here's where it gets controversial: could targeting a single enzyme be enough to turn the tide against cancers that have long resisted treatment?
Triple-negative breast cancer (TNBC), known for its resistance to many common therapies, presents a significant challenge because these cancer cells lack hormone receptors that drugs typically aim at. However, scientists led by Sanjay Malhotra from Oregon Health & Science University have identified an alternative target—an enzyme called enolase-1 (ENO1)—and a small molecule named SU212 that can interfere with its activity. Their findings, published in a recent study using a humanized mouse model, suggest that this approach might slow down the progression of TNBC.
So, what exactly does ENO1 do? It's a key player in glycolysis, the process by which cells break down glucose to produce energy. Specifically, ENO1 converts 2-phosphoglycerate into phosphoenolpyruvate, a crucial step in fueling cellular activity. Interestingly, ENO1 is often found in high amounts in various cancers and even in individuals with type 2 diabetes, hinting at its broader role in disease.
Malhotra explains that cancer cells have an insatiable appetite for glucose—they need massive amounts to sustain their rapid growth. ENO1 is central to this hunger, providing the sugars that fuel their relentless expansion. By blocking ENO1 with SU212, the researchers observed a slowdown in tumor growth and a reduction in tumor size in their mouse experiments.
What’s promising is that normal, healthy cells appear to be less dependent on ENO1, meaning that targeting this enzyme might specifically hit cancer cells without causing widespread damage. Although SU212 has not yet undergone testing in humans, Malhotra notes that initial safety assessments in dogs suggest a promising profile.
Looking ahead, Malhotra believes this small molecule could have potential beyond TNBC, possibly serving as a treatment for other cancer types or as part of combination therapies, especially for patients dealing with both TNBC and type 2 diabetes—since the molecule shows effects relevant to both conditions. Still, significant further research and development are necessary before it can become a clinical option.
Max Barnhart, a dedicated science reporter at C&EN, highlights that this innovative approach underscores the importance of exploring metabolic vulnerabilities in cancer. But the big question remains: can targeting enzymes like ENO1 truly revolutionize cancer treatment, or will cancer cells find ways to adapt? Share your thoughts—do you see this as a game-changer or a promising step in an ongoing battle?
